CABA:NSD-Cabaletta Bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.14

Change

+0.35 (+3.24)%

Market Cap

USD 0.26B

Volume

0.14M

Average Target Price

USD 21.50 (+93.00%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A

ETFs Containing CABA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.74% 37% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.74% 37% F 18% F
Trailing 12 Months  
Capital Gain 65.04% 66% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.04% 66% D 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.77% 39% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.77% 39% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 20.88% 95% A 73% C
Risk Adjusted Return 18.06% 46% F 40% F
Market Capitalization 0.26B 42% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 93% A 98% A+
Price/Book Ratio 2.35 78% C+ 60% D-
Price / Cash Flow Ratio -9.75 57% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.90% 80% B- 33% F
Return on Invested Capital -27.30% 74% C 25% F
Return on Assets -16.51% 72% C- 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 15.75 3% F 1% F
Short Percent 9.07% 37% F 23% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.